Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of FOLFOX vs gemcitabine in metastatic pancreatic adenocarcinoma patients unfit for FOLFIRINOX
2019-001364-30Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxaliplatin, folinic acid, fluorouracil and gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Overall survival at 24 months. Started Jul 2019; status: active.
02
Drugs
oxaliplatinfolinic acidfluorouracilgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2019-001364-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001364-30.